3 recruiting, 1 completed, 1 not yet recruiting. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Muscle Invasive Bladder Urothelial Carcinoma: new trials by email Literature Review of Muscle Invasive Bladder Urothelial Carcinoma trials Research Report on Muscle Invasive Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-11-03 |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer Enfortumab vedotin, Pembrolizumab - Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | Matthew Galsky | 75 | 2025-04-07 | 2026-08-05 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-11-06 |
| Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma gemcitabine, Cisplatin - Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | Phase 2 | Completed | Yung NA | 15 | 2024-02-02 | 2026-10-28 |
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
Magnetic Resonance Spectroscopy (3) · Cisplatin (2) · Cystoscopy (2) · Disulfides (2) · Gemcitabine (2) · Immunoglobulin G (2) · Specimen Handling (2) · pembrolizumab (2) · Cell-Free Nucleic Acids (1) · Circulating Tumor DNA (1) · Cystectomy (1) · Nivolumab (1) · Photons (1) · Radiation (1) · Synapsins (1)
National Cancer Institute (NCI) (2) · Matthew Galsky (1) · University of Washington (1) · Yung NA (1)
United States (4) · Canada (1) · Hong Kong (1)
Jonathan Wright, MD (1) · Leslie Ballas (1) · Matthew D Galsky (1) · Matthew Galsky, MD (1) · Yung Na, PHD (1)
U10CA180821 (1), U10CA180888 (1)